Archived Monthly Oncology Tumor Boards (June 2014 - June 2015)
NCCN is offering a series of twelve multidisciplinary case-based webinars on a variety of topics, including Lymphoma: Mantle Cell, Lymphoma: CLL/SLL, Chronic Phase CML, Multiple Myeloma, Breast Cancer: Adjuvant Systemic Therapy, Breast Cancer: Advanced Disease, Lung Cancer: Biomarker Driven Advanced Disease, Lung Cancer: Locally Advanced NSCLC: Stage IIIA Management, Metastatic Colorectal Cancer, Prostate Cancer: Castrate Resistant, Melanoma, and Kidney Cancer. Each webinar will be facilitated by two faculty members providing multidisciplinary perspectives. A different topic will be presented each month for twelve months (June 2014 until June 2015).
The NCCN Guidelines are a set of step-by-step evidence-based, consensus-driven recommendations that ensure that patients receive preventive, diagnostic treatment, and care that is most likely to lead to optimal outcomes. The NCCN recommendations are applicable to about 95% of patients. Clinicians need to consider the current clinical status of the patient, including general health, disease specifics, concomitant conditions, current and previous therapies, and the patients how to best apply appropriate standard of care including identifying circumstances where appropriate management requires adapting the NCCN Guidelines to the needs of the individual. This activity series will discuss the specific recommendations in the NCCN Guidelines as well as unique patient circumstances that impact how the NCCN Guidelines might be best applied.
These educational programs designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.
These activities are approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided for all sessions. Complete accreditation information is provided before each individual educational activity.
There are no fees for these activities.
These activities are supported by educational grants from AstraZeneca; Exelixis Inc.; Genentech BioOncology; Janssen Biotech, Inc.; Novartis Oncology; and Takeda Oncology. These activities are supported by a grant from Onyx Pharmaceuticals. These activities are supported by independent educational grants from Merck and Prometheus Laboratories Inc. These activities are supported by an unrestricted, educational grant from Celgene Corporation.